Table 3.
The proportion of participants who had high anti-RBD antibody levels (antibody level ≥ 133 BAU/ml) at 3 months after 1st dose of ChAdOx1 nCoV-19 vaccine and 1 month after 2nd dose of ChAdOx1 nCoV-19 vaccine.
| The proportion of participants who had high anti-RBD antibody levels after ChAdOx1 nCoV-19 vaccinnation. |
||||
|---|---|---|---|---|
| 3 months after 1st dose |
1 month after 2nd dose |
|||
| Antibody level (BAU/ml) ≥ 133 n (%) |
p-value | Antibody level (BAU/ml) ≥ 133 n (%) |
p-value | |
| Healthy controls | 82 (28.0) (n = 293) |
<.001 | 350 (99.4) (n = 352) |
<.001 |
| Co-morbid disease group | 53 (15.3) (n = 346) |
299 (82.4) (n = 363) |
||
n: number of participants. BAU: binding antibody unit. CI: confidence interval. Ref: reference group. p-value < .05: statistically significant.